<DOC>
	<DOC>NCT02969304</DOC>
	<brief_summary>The primary objective of this study is to estimate the proportion of DMF use that is prescribed "on-label" versus "off-label". The secondary objectives are: To describe the demographic characteristics and medical history of DMF users; To describe prescription drug history and concomitant medication use of DMF users; To describe the duration of therapy in participants newly initiating DMF treatment; To describe the medical specialties of DMF prescribers.</brief_summary>
	<brief_title>Study of Utilization Patterns of Dimethyl Fumarate in Germany</brief_title>
	<detailed_description>Dimethyl fumarate will not be provided to participants as a part of this study.</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key New users of dimethyl fumarate will be included in the analysis Key Patients for which data is not available for the 6 months period prior to the index date (baseline observational period) NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tecfidera</keyword>
	<keyword>Off-label</keyword>
	<keyword>Utilization</keyword>
</DOC>